Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer
- PMID: 36409970
- PMCID: PMC10166474
- DOI: 10.1200/PO.22.00145
Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer
Abstract
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a component of familial melanoma due to germline pathogenic variants (GPVs) in CDKN2A. However, it is unclear what role this gene or other genes play in its etiology.
Materials and methods: We analyzed 189 cancer predisposition genes using parametric rare-variant association (RVA) tests and nonparametric permutation tests to identify gene-level associations in PDAC for patients with (CDKN2A+) and without (CDKN2A-) GPV. Exome sequencing was performed on 84 patients with PDAC, 47 CDKN2A+ and 37 CDKN2A-. After variant filtering, various RVA tests and permutation tests were run separately by CDKN2A status. Genes with the strongest nominal associations were evaluated in patients with PDAC from The Cancer Genome Atlas and the UK Biobank (UKB). A secondary analysis including only GPV from UKB was also performed.
Results: In RVA tests, ERCC4 and RET showed the most compelling evidence as plausible PDAC candidate genes for CDKN2A+ patients. In contrast, the findings in CDKN2A- patients provided evidence for HMBS, EPCAM, and MRE11 as potential new candidate genes and confirmed ATM, BRCA2, and PALB2 as PDAC genes, consistent with findings in The Cancer Genome Atlas and the UKB. As expected, CDKN2A- patients were more likely to harbor GPVs from the 189 genes investigated. When including only GPVs from UKB, significant associations with PDAC were seen for ATM, BRCA2, and CDKN2A.
Conclusion: These results suggest that variants in other genes likely play a role in PDAC in all patients and that PDAC in CDKN2A+ patients has a distinct etiology from PDAC in CDKN2A- patients.
Conflict of interest statement
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (
Similar articles
-
Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.JAMA Oncol. 2023 Jul 1;9(7):955-961. doi: 10.1001/jamaoncol.2023.0806. JAMA Oncol. 2023. PMID: 37200008 Free PMC article.
-
Germline Pathogenic Variants in Patients with Pancreatic Ductal Adenocarcinoma and Extra-Pancreatic Malignancies: A Nationwide Database Analysis.Mod Pathol. 2025 May;38(5):100709. doi: 10.1016/j.modpat.2025.100709. Epub 2025 Jan 9. Mod Pathol. 2025. PMID: 39793706
-
Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance.Elife. 2022 Jan 10;11:e71137. doi: 10.7554/eLife.71137. Elife. 2022. PMID: 35001868 Free PMC article.
-
The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.Pancreas. 2021 Sep 1;50(8):1123-1130. doi: 10.1097/MPA.0000000000001888. Pancreas. 2021. PMID: 34714275 Free PMC article. Review.
-
A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer.J Gastroenterol. 2021 Aug;56(8):713-721. doi: 10.1007/s00535-021-01806-y. Epub 2021 Jul 13. J Gastroenterol. 2021. PMID: 34255164 Free PMC article.
Cited by
-
High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.J Transl Med. 2024 Feb 20;22(1):184. doi: 10.1186/s12967-024-04989-z. J Transl Med. 2024. PMID: 38378604 Free PMC article.
-
Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity.Cell Death Discov. 2025 Mar 16;11(1):106. doi: 10.1038/s41420-025-02382-3. Cell Death Discov. 2025. PMID: 40091075 Free PMC article.
-
Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts.Leukemia. 2025 Feb;39(2):400-411. doi: 10.1038/s41375-024-02436-y. Epub 2024 Nov 6. Leukemia. 2025. PMID: 39501104 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous